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ABSTRACT
Background The functional effects of abnormal
diffusing capacity for carbon monoxide (DLCO) in
ex-smokers without chronic obstructive pulmonary
disease (COPD) are not well understood.
Objective We aimed to evaluate and compare well
established clinical, physiological and emerging imaging
measurements in ex-smokers with normal spirometry and
abnormal DLCO with a group of ex-smokers with normal
spirometry and DLCO and ex-smokers with Global
Initiative for Chronic Obstructive Lung Disease (GOLD)
stage I COPD.
Methods We enrolled 38 ex-smokers and 15 subjects
with stage I COPD who underwent spirometry,
plethysmography, St George’s Respiratory Questionnaire
(SGRQ), 6 min Walk Test (6MWT), x-ray CT and
hyperpolarised helium-3 (3He) MRI. The 6MWT distance
(6MWD), SGRQ scores, 3He MRI apparent diffusion
coefficients (ADC) and CT attenuation values below
−950 HU (RA950) were evaluated.
Results Of 38 ex-smokers without COPD, 19 subjects
had abnormal DLCO with significantly worse ADC
(p=0.01), 6MWD (p=0.008) and SGRQ (p=0.01) but
not RA950 (p=0.53) compared with 19 ex-smokers with
normal DLCO. Stage I COPD subjects showed significantly
worse ADC (p=0.02), RA950 (p=0.0008) and 6MWD
(p=0.005), but not SGRQ (p=0.59) compared with
subjects with abnormal DLCO. There was a significant
correlation for 3He ADC with SGRQ (r=0.34, p=0.02)
and 6MWD (r=−0.51, p=0.0002).
Conclusions In ex-smokers with normal spirometry and
CT but abnormal DLCO, there were significantly worse
symptoms, 6MWD and 3He ADC compared with ex-
smokers with normal DLCO, providing evidence of the
impact of mild or early stage emphysema and a better
understanding of abnormal DLCO and hyperpolarised
3He
MRI in ex-smokers without COPD.
INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is
characterised by chronic progressive expiratory
flow limitation that develops as a result of the
lung’s inflammatory response to inhaled toxic gases
and particles, primarily from tobacco smoke.1 In
COPD, airflow limitation is caused by both small
airway disease (obstructive bronchiolitis) and paren-
chymal destruction (emphysema)1 but the relative
contributions of these pathologies vary from
person to person.
When COPD is suspected based on symptoms,
such as dyspnoea, chronic cough or sputum pro-
duction, and/or a history of exposure to risk
factors,1 airflow limitation is measured using spir-
ometry and severity is determined according to the
Global Initiative for Chronic Obstructive Lung
Disease (GOLD) criteria.1 This approach, however,
has been acknowledged to potentially result in an
over diagnosis of COPD in the elderly,2 as well as
under diagnosis of mild or early stage COPD.3
Key messages
What is the key question?
▸ The functional effects of abnormal DLCO in
ex-smokers without airflow limitation are not
well understood. To try to better understand
the role of abnormal DLCO in ex-smokers
without COPD, we evaluated and compared
clinical, physiological and emerging imaging
measurements in ex-smokers with normal
spirometry and DLCO, ex-smokers with normal
spirometry but abnormal DLCO and those with
GOLD stage I COPD.
What is the bottom line?
▸ We evaluated 53 ex-smokers including 15
subjects with stage I COPD and 38 subjects
without airflow limitation. Of the 38
ex-smokers without airflow limitation, 19 had
abnormal DLCO and significantly worse
symptoms, 6MWD and 3He ADC compared
with the 19 ex-smokers with normal DLCO
although CT derived measurements of
emphysema were not significantly different.
Why read on?
▸ Abnormal DLCO in ex-smokers without airflow
limitation was related to worse symptoms,
exercise capacity and 3He ADC compared with
ex-smokers with normal DLCO, providing
evidence of the impact of DLCO abnormalities
consistent with early or very mild emphysema
and revealed by 3He MRI but not CT. Abnormal
DLCO measurements in ex-smokers without
COPD should be followed-up to evaluate
potential progression of disease.
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The COPDGene study recently reported low forced expira-
tory volume in 1 s (FEV1) and normal FEV1/forced vital cap-
acity (FVC) in ex-smokers with significant symptoms and
decreased 6 min Walk Distance (6MWD), and defined these
patients as GOLD unclassified (GOLD-U).4 Until now,
ex-smokers with GOLD-U or those with ‘non-obstructive’ or
‘pure’ emphysema without airflow limitation have been system-
atically excluded from COPD studies. With respect to non-
obstructive emphysema, there have been a few case reports5–7
and pilot studies8 that described significant smoking history,
severe symptoms and abnormal diffusing capacity for carbon
monoxide (DLCO) in patients concomitant with normal expira-
tory airflow. A recent study also reported that otherwise normal
asymptomatic smokers with abnormal DLCO showed evidence
of endothelial microparticles in the circulation—a marker of
early lung destruction associated with emphysema.9 Although
abnormal DLCO in ex-smokers is a valuable marker of lung
function impairment, even in the absence of airflow limitation,
the relationship between DLCO with other functional markers
(ie, symptoms and exercise limitation) is not well understood.
We hypothesised that subjects with abnormal DLCO without
airflow limitation would have imaging evidence of early or mild
emphysema with measureable functional consequences.
Multidetector CT and hyperpolarised helium-3 (3He) MRI
have been used independently to measure emphysema and
airways disease as distinct phenotypes in COPD.10 11 In particu-
lar, hyperpolarised 3He MRI apparent diffusion coefficients
(ADC)12 13 provide a way to sensitively measure regional lung
tissue destruction—the hallmark of emphysema. Abnormally
elevated 3He ADC have previously been reported in asymptom-
atic smokers without COPD14 15 although the relationship
between 3He MRI ADC in early disease with symptoms and
other physiological measurements has never been reported and
their functional impact is not known. To better understand the
consequences of early or mild disease in ex-smokers, we have
evaluated well established clinical, physiological as well as emer-
ging imaging measurements in ex-smokers with normal spirom-
etry but abnormal DLCO as well as ex-smokers with GOLD
stage I COPD and those with normal spirometry and DLCO.
MATERIALS AND METHODS
Study subjects
All subjects provided written informed consent to the protocol
approved by the local research ethics board and Health Canada,
and the study was compliant with the Personal Information
Protection and Electronic Documents Act (Canada) and the
Health Insurance Portability and Accountability Act (USA).
Ex-smokers were recruited from a local tertiary care centre and by
advertisement. Thirty-eight subjects were enrolled who were
ex-smokers without a diagnosis of COPD and 15 ex-smokers were
enrolled with a previous diagnosis of GOLD stage I COPD,1 all of
whom were 60–85 years of age, with a smoking history ≥10 pack-
years. Subjects without a diagnosis of COPD had no history of pre-
vious chronic or current respiratory disease and were classified
according to American Thoracic Society/European Respiratory
Society recommendations16 on the approximate lower limits of
normal for DLCO,
17 such that normal is defined as
DLCO≥75%pred and abnormal DLCO<75%pred.
Spirometry, plethysmography and other tests
Spirometry was performed using an EasyOne spirometer
(Medizintechnik AG, Zurich, Switzerland) according to the
American Thoracic Society guidelines.18 Lung volumes were
measured using body plethysmography and DLCO was assessed
using the attached gas analyser (MedGraphics Corporation,
St Paul, Minnesota, USA). The St Georges Respiratory
Questionnaire (SGRQ) was administered19 20 and a standard
6 min Walk Test (6MWT)21 was performed.
Image acquisition
MRI was performed on a whole body 3.0 T Discovery 750MR
(General Electric Health Care, Milwaukee, Wisconsin, USA)
MRI system.22 3He gas was polarised to 30–40% (HeliSpin) and
doses (5 ml/kg body weight) were administered in 1.0 l Tedlar
bags diluted with medical grade nitrogen (N2) (Linde, Ontario,
Canada). 3He MRI diffusion weighted images were acquired
using a fast gradient recalled echo sequence immediately follow-
ing inhalation of the 3He/N2 gas mixture during breath hold con-
ditions.22 Two interleaved images were acquired (14 s total data
acquisition, repetition time (TR)/echo time (TE)/flip angle=7.6
ms/3.7 ms/8°, field of view (FOV)=40×40 cm, matrix 128×128,
seven slices, 30 mm slice thickness, 0 gap), with and without add-
itional diffusion sensitisation with b=1.6 s/cm2 (gradient ampli-
tude (G)=1.94 G/cm, rise and fall time=0.5 ms, gradient
duration=0.46 ms, diffusion time=1.46 ms).
CT was performed on a 64 slice Lightspeed VCT scanner
(General Electric Health Care) (64×0.625 mm, 120 kVp, 100
effective mA, tube rotation time=500 ms, pitch=1.0). A single
spiral acquisition was acquired in breath hold after inhalation of
1.0 l of N2 from functional residual capacity. Reconstruction
was performed (1.25 mm) using a standard convolution kernel.
To minimise the potential for differences in the levels of
inspiration between 3He MRI and CT, extensive coaching was
performed prior to the imaging sessions to ensure subjects could
completely inspire the contents of the 1.0 l bag. The order of
3He MRI and CTacquisition was randomised for each subject.
Image analysis
Regions of signal void were quantified as the 3He ventilation
defect per cent (VDP).23 3He ADC maps were also generated as
previously described.24 Regional differences in ADC were evalu-
ated in the anterior–posterior (AP) direction.25 The AP gradient
(APG) was the slope of the line of best fit that described the
change in ADC as a function of distance (in cm). Analysis of CT
was performed using the Pulmonary Workstation 2.0 (VIDA
Diagnostics Inc, Coralville, Iowa, USA). Wall area per cent (WA
%) was measured for the segmental and subsegmental airways10
and the relative area with attenuation values below −950 HU
(RA950) was generated.
26
Statistical methods
A multivariate analysis of variance was performed using IBM
SPSS Statistics V.20.0 (SPSS Inc, Chicago, Illinois, USA).
Univariate comparisons were performed using an unpaired two
tailed t test, and Welch’s correction was used when the F test
for equal variances was significant using GraphPad Prism V.4.00
(GraphPad Software Inc, San Diego, California, USA). A
Fisher’s exact test was performed for categorical variables.
Linear regression (r2) and Pearson correlation coefficients (r)
were used to determine correlations using GraphPad Prism
V.4.00. Results were considered significant when the probability
of making a type I error was less than 5% (p<0.05).
RESULTS
We enrolled 53 ex-smokers, 38 subjects without a diagnosis of
COPD and 15 subjects diagnosed with stage I COPD. Of the 38
ex-smokers without COPD, half had normal DLCO
without airflow obstruction (ND, n=19) and the other half had
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abnormal DLCO without airflow obstruction (AD, n=19). Table 1
shows the subject demographics as well as pulmonary function,
SGRQ, 6MWD, CT and 3He MRI measurements for all subjects
categorised according to their spirometry and DLCO results.
Subjects with abnormal DLCO without airflow obstruction
(AD) were not significantly different from ex-smokers with
normal DLCO (ND) and stage I COPD subjects with respect to
age, BMI, pack-years, years since smoking cessation, change in
SpO2 after the 6MWT, CT WA% and
3He VDP. However, there
were significantly more female AD subjects than ND (p=0.02)
and stage I COPD (p=0.01) subjects.
Figure 1 shows the central coronal 3He MRI static ventilation
image and 3He MRI ADC map for subjects with ND, AD and
stage I COPD. As shown in table 1, AD subjects had a signifi-
cantly worse 3He ADC (0.30±0.03 cm2/s; p=0.01), 6MWD
(341±95 m; p=0.008) and SGRQ total score (29±21; p=0.01)
compared with ND subjects, but there was no significant differ-
ence for RA950 (p=0.53). In comparison with stage I COPD,
AD subjects had a significantly reduced 6MWD (341±95 m;
p=0.005), FVC (93±12%pred; p=0.001), RA950 (1.6±1.1;
p=0.0008) and ADC (0.30±0.03 cm2/s; p=0.02), and a signifi-
cantly greater FEV1/FVC (80±7%; p<0.0001) and no signifi-
cant difference for SGRQ total score (p=0.59).
Figure 2A shows the mean ADC on a slice by slice basis in the
anterior to posterior direction for ND, AD and stage I COPD
subjects. For AD ex-smokers, the ADC gradient in the anterior–
posterior direction (ADC APG) was significantly lower than for
ND (p=0.02) and not significantly different from COPD sub-
jects (p=0.20). Figure 2B shows the significant correlation
between ADC APG and the 6MWD (r=−0.51, p=0.0002).
Figure 3 shows the correlations between 3He ADC and CT
RA950 with DLCO, SGRQ and 6MWD. There was a significant
correlation between 3He ADC and DLCO (r=−0.55, p<0.0001)
and SGRQ (r=0.34, p=0.02) but not 6MWD (r=−0.17,
p=0.24), and as shown in figure 2B, ADC APG was significantly
correlated with 6MWD. RA950 was significantly correlated with
DLCO (r=−0.31, p=0.03) but not SGRQ (r=0.24, p=0.10) or
6MWD (r=0.0013, p=0.99).
Table 1 Clinical, functional and radiographic measurements of asymptomatic ex-smokers with normal and abnormal diffusion capacity of the
lung for carbon monoxide, compared with GOLD stage I chronic obstructive pulmonary disease
ND (n=19) AD (n=19) Stage I COPD (n=15)
Significance of difference (p)
ND–AD AD–COPD
Subject demographics
Age (years) 71 (7) 74 (7) 77 (5) 0.09 0.30
No of women (n) 3 11 2 0.02 0.01
BMI (kg/m2) 29.5 (3.4) 28.6 (4.0) 28.4 (4.0) 0.46 0.91
Pack-years 25 (12) 32 (23) 49 (36) 0.25 0.11
Time since quitting (years) 26 (9) 24 (14) 21 (14) 0.63 0.63
Pulmonary function tests
FEV1%pred 107 (13) 99 (12) 95 (13) 0.07 0.34
FVC %pred 98 (12) 93 (12) 108 (14) 0.16 0.001
FEV1/FVC 80 (6) 80 (7) 63 (5) 0.73 <0.0001
IC %pred 112 (17) 103 (22) 103 (17) 0.17 0.99
RV %pred 103 (17) 107 (25) 114 (29) 0.58 0.45
TLC %pred 101 (10) 101 (15) 109 (13) 0.96 0.12
RV/TLC %pred 101 (13) 104 (16) 103 (18) 0.49 0.77
DLCO %pred 89 (9) 59 (13) 68 (19) <0.0001 0.12
6MWT
Pre 6MWT SpO2% 97 (2) 95 (2) 95 (2) 0.06 0.57
Δ 6MWT SpO2% 0 (2)* 0 (2)† −1 (3) 0.55 0.25
Distance (m) 430 (99) 341 (95) 417 (41) 0.008 0.005
SGRQ
Symptoms 18 (17)* 36 (30)* 36 (22) 0.04 0.99
Activity score 19 (21)† 41 (24) 36 (25)‡ 0.006 0.54
Impact score 6 (11)† 17 (18) 15 (13)‡ 0.04 0.68
Total score 12 (14)§ 29 (21) * 25 (17)‡ 0.01 0.59
CT measurements
RA950 1.36 (1.25) 1.60 (1.06) 5.50 (3.16) 0.53 0.0008
WA% 57 (4) 59 (2) 58 (2) 0.17 0.23
3He MRI measurements
ADC (cm2/s) 0.27 (0.03)* 0.30 (0.03)§ 0.36 (0.08) 0.01 0.02
VDP (%) 6 (3)* 7 (4)§ 9 (5)‡ 0.40 0.07
Values are mean (SD).
Missing values: SpO2 not recorded post-6MWT (n=1, normal DLCO; n=2, abnormal DLCO); incomplete SGRQ questionnaire (n=3, normal DLCO; n=1, abnormal DLCO; n=1, COPD); and
image acquisition failures (n=1, normal DLCO; n=2, abnormal DLCO; n=1, COPD).
*n=18, †n=17, ‡n=14, §n=16.
AD, abnormal DLCO; ADC, apparent diffusion coefficient; BMI, body mass index; COPD, chronic obstructive pulmonary disease; DLCO, diffusion capacity of the lung for carbon monoxide;
FEV1, forced expiratory volume in 1 s; FVC, force vital capacity; GOLD, Global Initiative for Chronic Obstructive Lung Disease; IC, inspiratory capacity; 6MWT, 6 min Walk Test; ND,
normal DLCO; RA950, relative area with attenuation values below −950 HU; RV, residual volume; SGRQ, St George’s Respiratory Questionnaire; SpO2, peripheral oxygen saturation; TLC,
total lung capacity; VDP, ventilation defect per cent; WA%, wall area per cent.
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DISCUSSION
To better understand the relationship between lung structural
markers, symptoms and physiological measurements in
ex-smokers, we evaluated 53 ex-smokers, including 38 subjects
who did not have a diagnosis of COPD and 15 subjects with
stage I COPD, and observed the following. (1) Nineteen of 38
ex-smokers showed normal spirometry and CT but abnormal
DLCO and 19/38 ex-smokers showed normal spirometry,
CT and DLCO. (2) Subjects with abnormal DLCO had signifi-
cantly worse 6MWD compared with stage I COPD ex-smokers
and significantly worse 3He ADC, SGRQ and 6MWD compared
with subjects with normal DLCO. (3) Subjects with abnormal
DLCO had significantly smaller
3He MRI ADC AP gradients
compared with subjects with normal DLCO.
We were surprised that half of the ex-smokers without COPD
showed abnormal DLCO and significantly worse
3He ADC, but
Figure 1 Helium-3 (3He) MRI static
ventilation images and 3He apparent
diffusion coefficient (ADC) maps for a
representative ND and two
representative AD and COPD stage I
ex-smokers. ND subject is a
70-year-old man with FEV1=101%pred,
FEV1/FVC=0.75, DLCO=113%pred,
3He
ADC=0.26 cm2/s and CT RA950=1.25.
AD subject No 1 is a 74-year-old man
with FEV1=89%pred, FEV1/FVC=0.77,
DLCO=41%pred,
3He ADC=0.31 cm2/s
and CT RA950=1.52. AD subject No 2
is a 74-year-old man with
FEV1=95%pred, FEV1/FVC=0.85,
DLCO=63%pred,
3He ADC=0.29 cm2/s
and CT RA950=0.52. GOLD stage I
COPD subject No 1 is a 74-year-old
man with FEV1=86%pred, FEV1/
FVC=0.59, DLCO=45%pred,
3He
ADC=0.37 cm2/s and CT RA950=6.14.
GOLD stage I COPD subject No 2 is a
78-year-old man with FEV1=118%pred,
FEV1/FVC=0.62, DLCO=71%pred,
3He
ADC=0.38 cm2/s and CT RA950=5.52.
AD, abnormal DLCO; COPD, chronic
obstructive pulmonary disease; DLCO,
diffusion capacity of the lung for
carbon monoxide; FEV1, forced
expiratory volume in 1 s; FVC, force
vital capacity; GOLD, Global Initiative
for Chronic Obstructive Lung Disease;
ND, normal DLCO; RA950, relative area
with attenuation values below −950
HU.
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with normal CT, which, based on previous studies,14 15 was an
unexpected result. Although we were not able to confirm signifi-
cant disease other than emphysema that could account for these
findings, we note that a previous evaluation14 of 10 younger
asymptomatic smokers (mean age=47 years, range=23–73)
showed that three of five subjects aged 60 years or older also
reported DLCO<75%pred. In ex-smokers, abnormal DLCO is
thought to reflect diminished lung surface area available for gas
exchange although DLCO also reflects the volume of blood in the
pulmonary capillaries and thickness of the alveolar capillary
membrane,27 related to bronchiectasis and interstitial lung
disease.28 Abnormally low DLCO is also consistent with pulmon-
ary vascular disease,29 and such patients exhibit normal spirom-
etry, dyspnoea on exertion30 and a decline in oxygen saturation
with exertion.31 In the current study, AD subjects did not show
reduced oxygen saturation during the 6MWT nor did they
report a history of pulmonary vascular disease, so there was no
evidence to support the notion that pulmonary vascular disease
was responsible for the abnormal exercise performance and dys-
pnoea observed here. Although DLCO is a very sensitive marker
of emphysema in smokers,8 reproducibility can be low, and in
some cases, low to moderate correlations have been reported
between DLCO and pathological assessments of emphysema.
32 33
Previous work by Woods and Hogg34 compared 3He ADC
with histology measurements of emphysema in explanted lungs
and showed that ADC values could be used to distinguish
normal from emphysematous lung tissue with greater precision
than the mean linear intercept measurement from histology
samples. Another previous study in COPD showed that while
3He ADC correlated significantly with CT measurements (ie,
RA950), stronger correlations were observed for
3He ADC and
DLCO than for RA950 and DLCO.
35 In asymptomatic smokers,
3He ADC was shown to correlate with DLCO, but there was no
significant correlation between DLCO and CT RA950.
14 Finally,
abnormally elevated 3He ADC values were previously observed
in never smokers exposed to significant second hand-smoke36
compared with never smokers with no such exposure. Taken
together, these previous findings support the observation here
that elevated 3He ADC in ex-smokers with abnormal DLCO may
reflect mild emphysema not detected by CT. Our observations
are also consistent with previous reports5–8 37 and the identifica-
tion of mild emphysema using histology that was not predicted
using preoperative CT.38 39 While we cannot rule out the pres-
ence of small airways disease in subjects with AD, there was no
significant difference between the AD and ND subjects for 3He
VDP and CT WA%, both of which provide estimates of airways
disease. Taken together, these results suggest that 3He ADC is
sensitive to very mild emphysema in subjects with abnormal
DLCO who have no CT evidence of airways disease or
emphysema.
Concomitant with significantly elevated 3He ADC, we
observed significantly worse 6MWD in AD compared with
COPD and ND ex-smokers. This is an important finding and
the first to provide evidence of a relationship between 3He MRI
ADC reflective of early or mild emphysema and exercise cap-
acity. It is also important to note that the ratio of female/male
ex-smokers with AD was 11/8 (1.4), and for ND this ratio was
3/16 (0.2). Although the current study was not powered to
evaluate sex differences, previous evidence suggests that female
sex is significantly associated with early onset COPD.40 41
However, previous studies have also shown that emphysema
dominates in men compared with women,42 whereas here the
sex ratio was reversed. We note that imaging was performed at a
fixed volume and because there were more women in the AD
group (who potentially had smaller lungs), we investigated the
relationship between lung size and 3He ADC and observed no
correlation for 3He ADC with height (r=−0.36, p=0.18), total
lung capacity (r=0.33, p=0.21) or thoracic cavity volume
(r=−0.20, p=0.45). Therefore, the elevated ADC in the AD
subjects observed here was not related to lung size and cannot
explain the preponderance of female subjects in the AD sub-
group. Consistent with our findings, the 6MWD in COPD was
also previously shown to be lower for FEV1 matched women
versus men.43
We took advantage of the fact that 3He MRI diffusion
weighted images were acquired in the supine position and
Figure 2 Regional helium-3 (3He) MRI ADC anterior–posterior gradients (APG) for ND, AD and stage I COPD subjects, and correlation between
3He ADC APG with 6MWD. (A) Mean APG was statistically significantly different for AD and ND subjects (AD: APG=−3.55×10−4±4.85×10−4 cm2/s/cm;
ND: APG=−7.03×10−4±3.03×10−4 cm2/s/cm; p=0.02) but not between the AD and stage I COPD subjects (COPD: APG=−5.58×10−4±
3.73×10−4 cm2/s/cm; p=0.20). Error bars represent the ADC SD for each image slice. (B) 3He APG ADC was significantly correlated with 6MWD
(r=−0.51, p=0.0002, r2=0.26, p=0.0002, y=−0.02x+4.4). Dotted lines represent the 95% CIs of the regression. AD, abnormal DLCO; ADC, apparent
diffusion coefficient; COPD, chronic obstructive pulmonary disease; DLCO, diffusion capacity of the lung for carbon monoxide; 6MWT, 6 min Walk
Test; ND, normal DLCO.
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measured compression of the dependent lung due to gravity.
Several sites have reported smaller 3He ADC in the dependent
lung (or posterior slices) relative to the non-dependent lung,25
44 45 likely due to gravitational compression of the parenchyma.
In COPD subjects,25 44 this anterior to posterior difference is
significantly smaller and this is thought to be due to regional gas
trapping that counteracts gravitational compression of the
dependent regions. Here we observed that these gradients were
significantly smaller in AD subjects compared with ND subjects,
suggesting that regional gas trapping was greater in the AD
subgroup.
Finally, we showed that 3He ADC was significantly correlated
with SGRQ and that 3He ADC APGs were significantly corre-
lated with the 6MWD. The significant relationships between
3He ADC with respiratory symptoms and exercise capacity
suggest that in early emphysema, symptomatic changes can go
unnoticed in older patients even when standardised tests report
significant changes in health related quality of life and exercise
capacity. While elevated 3He ADC in asymptomatic ex-smokers
was previously described,14 15 the imaging to exercise capacity
and imaging to symptoms correlations observed here in very
early emphysema are novel findings. The unexpected finding of
3He ADC AP gradient correlations with 6MWD also provides
more evidence about the role of mild emphysema and regional
gas trapping that may together lead to exercise limitation even
in early disease. AD ex-smokers also reported a SGRQ that was
not significantly different from the stage I COPD ex-smokers,
and worse than ND subjects, which supports previous reports
of compromised health related quality of life46 and reduced
work capacity in very early disease.47
This study was limited by the relatively small number of sub-
jects evaluated, although we note that this is the single largest
prospective study that directly compared CT, symptoms, exer-
cise capacity and 3He MRI in ex-smokers with and without
airflow obstruction. We admit that we were surprised to find
such a large proportion of asymptomatic ex-smokers without
airflow limitation and abnormal DLCO in this study. This finding
raises the important question of whether this subgroup is
Figure 3 Correlation between
helium-3 (3He) ADC and CT RA950 with
DLCO, SGRQ and 6MWD for ND, AD
and stage I COPD subjects. (A) 3He
ADC was significantly correlated with
DLCO (r=−0.55, p<0.0001, r2=0.31,
p<0.0001, y=−0.0018x+0.44) and
SGRQ (r=0.34, p=0.02, r2=0.12,
p=0.02, y=0.0012x+0.28) but not with
6MWD (r=−0.17, p=0.24, r2=0.03,
p=0.24, y=−0.00013x+0.36). (B) CT
RA950 was significantly correlated with
DLCO (r=−0.31, p=0.03, r2=0.09,
p=0.02, y=−0.040x+5.42) but not
with SGRQ (r=0.24, p=0.10, r2=0.06,
p=0.10, y=−0.034x+1.71) or 6MWD
(r=0.0013, p=0.99, r2<0.0001,
p=0.99, y=0.00003x+2.5). Dotted lines
represent the 95% CIs of the
regression. AD, abnormal DLCO; ADC,
apparent diffusion coefficient; COPD,
chronic obstructive pulmonary disease;
DLCO, diffusion capacity of the lung for
carbon monoxide; 6MWT, 6 min Walk
Test; ND, normal DLCO; RA950, relative
area with attenuation values below
−950 HU; SGRQ, St George’s
Respiratory Questionnaire.
Kirby M, et al. Thorax 2013;68:752–759. doi:10.1136/thoraxjnl-2012-203108 757
Respiratory research
Acquisitions Unit. Protected by copyright.
 o
n
 M
arch 3, 2020 at Univ O
f W
est O
ntario G
STR101749364 Serials
http://thorax.bmj.com/
Thorax: first published as 10.1136/thoraxjnl-2012-203108 on 19 April 2013. Downloaded from 
atypical or perhaps this is a unique finding because ‘asymptom-
atic’ ex-smokers are rarely administered the SGRQ or the
6MWT. Importantly, the selection criteria, manner and location
for subject recruitment are those we have previously used for
the recruitment of older ex-smokers, and typical of other
studies. It is possible that in this unique subgroup, patients were
less likely to recognise and report symptoms. Our results cer-
tainly raise many intriguing questions regarding whether these
subjects are unusual or whether we have simply uncovered a
group of older ex-smokers with both unrecognised mild emphy-
sema and functional limitations.
In summary, we evaluated 38 ex-smokers without airflow
limitation and 15 ex-smokers with COPD. In the absence of
spirometry or CT abnormalities, half of the ex-smokers without
COPD showed abnormal DLCO and abnormally elevated
3He
ADC, consistent with early or mild emphysema. These subjects
had significantly and markedly worse 6MWD and SGRQ com-
pared with ex-smokers with normal ADC and DLCO, and worse
6MWD than subjects with COPD. These findings provide a
better understanding of abnormal DLCO in ex-smokers without
COPD.
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